The FDA has approved tocilizumab-aazg (Tyenne), the first tocilizumab biosimilar, for treating rheumatic diseases, as well as the new drug application for CB-101, a chimeric antigen receptor T cell therapy, for treating lupus nephritis and extra-renal lupus.
As they usually are, the pediatrics are absolutely correct: A child is not just a little adult. The same can be said for the eldest among us: Senior citizens are more than just old adults; they have their own biopsychosocial considerations that we, as rheumatologists, must tend to. Among all the conditions that we find…
Originally posted Feb. 13, 2023; reposted in conjunction with publication of the PMR supplement to the February 2024 issue of The Rheumatologist. PHILADELPHIA—Polymyalgia rheumatica (PMR) is a chronic inflammatory condition that almost exclusively affects individuals older than 50.1 First described in 1888, PMR has been a recognized rheumatic disease since at least 1957. Diagnosing the…
A minority of patients with polymyalgia rheumatica (PMR) who were new to rheumatology practice were prescribed steroid-sparing agents through two years of follow-up. This is according to a large, U.S.-based cohort study, published in Arthritis Care & Research, which also found that nearly two-thirds of the patients remained on glucocorticoids beyond one year.1 “Our study…
Background/Purpose Polymyalgia rheumatica (PMR) treatment is primarily based on long-term corticosteroids, which results in significant toxicities. Studies have shown that patients with PMR are exposed to years of corticosteroid treatment.1,2 In a single academic center cohort, we found that 76% of patients remained on steroids at the end of two years.3 In a second cohort…
SAN DIEGO—In recent years, the recognition of nr-axSpa has helped identify the cause of back pain in many patients previously without a diagnosis. However, questions remain about how to avoid under- or over-diagnosing the condition. In the session titled, Pearls and Pitfalls in Diagnosing Non-Radiographic Axial Spondyloarthritis, several speakers provided high-yield insights on this topic. Diagnostic challenges, imaging options and mimics to watch for were among the specific points of discussion.
This year, tocilizumab biosimilars have been approved to treat adult and pediatric patients with rheumatic disease, including rheumatoid arthritis, juvenile idiopathic arthritis and more, in both Europe and the U.S.
A Roshi (i.e., master) apparently said that in Zen, “there is nothing to believe and everything to discover.” Interestingly enough, I have never been able to confirm who actually said that, which makes this saying about belief and discovery particularly apt. Regardless, I think about those words at least twice a day when I am…
One of the most fun events at every annual meeting is the ACR Knowledge Bowl. In this quiz show-style trivia game, fellows form teams to compete for top prizes. There’s a charismatic host, a panel of esteemed judges and an auditorium packed with cheering spectators. Beyond the fun of competing against your peers from other…
In 1949, the first description of patients with rheumatoid arthritis (RA) given cortisone sent shockwaves through the medical community, quickly capturing the public imagination as well. The paradigm-shifting report paved the way for the use of cortisone and related drugs in RA and many other medical conditions.1 The following is a discussion of some of…